CTOs on the Move

Sammons Preston Inc

www.sammonsprestonrolyan.com

 
Sammons Preston Inc is a Bolingbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

MedLite ID

MedLite ID is an easy-to-use, disposable medical device that enables clinicans to accurately and efficiently identify a single medication infusion line against similar infusion lines in any light setting. The ninth leading cause of medical-error deaths in the United States involves infusion line confusion, and nearly 65 percent of those cases are related to the medication infusion line. MedLite ID eliminates infusion confusion by providing indicators with built-in wireless light technology at the medication bag, connector, and to patient. Each MedLite ID device is unique to its individual medication infusion line and cuts the process of infusion line identification to mere seconds. This saves clinicians precious time while also drastically mitigating risk and reducing stress while ensuring better care and patient outcomes.

Fieldtex Products Inc

Fieldtex Products Inc is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progressive Medical International

Progressive Medical International is a Vista, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MD Buyline

MD Buyline is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GT Medical Technologies

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.